コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of AP-1 and Sp1 with the OPN promoter using chromatin immunoprecipitation assay.
2 everal downstream target genes of AtERF53 by chromatin immunoprecipitation assay.
3 binding on its promoter relative to NFs in a chromatin immunoprecipitation assay.
4 o binding to the LCR of both HPV types using chromatin immunoprecipitation assay.
5 ith the E-cadherin promoter was evidenced by chromatin immunoprecipitation assay.
6 d to the AP-1 site, which was confirmed by a chromatin immunoprecipitation assay.
7 d the TNF-alpha promoter was demonstrated by chromatin immunoprecipitation assay.
8 HNF4alpha to Agxt2 promoter was confirmed by chromatin immunoprecipitation assay.
9 and TNFA loci were investigated by using the chromatin immunoprecipitation assay.
10 hown by oligonucleotide-binding assay and by chromatin immunoprecipitation assay.
11 teraction was further confirmed in vivo by a chromatin immunoprecipitation assay.
12 wo integrins were furthermore evidenced by a chromatin immunoprecipitation assay.
13 ion target of FOXM1 by promoter analysis and chromatin-immunoprecipitation assay.
14 e LPA1 gene promoter was further verified by chromatin immunoprecipitation assays.
15 ha binding to the MMP13 proximal promoter in chromatin immunoprecipitation assays.
16 depletion of H-NS at the promoter region in chromatin immunoprecipitation assays.
17 rate that CREB is a direct target of Sox4 by chromatin immunoprecipitation assays.
18 tified by electrophoretic mobility shift and chromatin immunoprecipitation assays.
19 oprecipitation, DNA pull-down, reporter, and chromatin immunoprecipitation assays.
20 ecognize native yeast proteasome subunits in chromatin immunoprecipitation assays.
21 el shift assays and to the MMP-9 promoter in chromatin immunoprecipitation assays.
22 cells by electrophoretic mobility shift and chromatin immunoprecipitation assays.
23 tected by electrophoretic mobility shift and chromatin immunoprecipitation assays.
24 were demonstrated by gel mobility shift and chromatin immunoprecipitation assays.
25 R), and H3K9me3 levels at their promoters by chromatin immunoprecipitation assays.
26 promoter in a cell cycle-dependent manner in chromatin immunoprecipitation assays.
27 eporter, electrophoretic mobility shift, and chromatin immunoprecipitation assays.
28 otid arteries and in cultured VSMCs based on chromatin immunoprecipitation assays.
29 ivity and studied in immunoprecipitation and chromatin immunoprecipitation assays.
30 -kappaB subunit p65 in cells was analyzed in chromatin immunoprecipitation assays.
31 e polymerase chain reaction, immunoblot, and chromatin immunoprecipitation assays.
32 g to the promoter regions of target genes in chromatin immunoprecipitation assays.
33 evaluated with oligonucleotide pull-down and chromatin immunoprecipitation assays.
34 ated the TGFbeta2 promoter in luciferase and chromatin immunoprecipitation assays.
35 of genes encoding microRNAs was assessed by chromatin immunoprecipitation assays.
36 rase reporter, site-directed mutagenesis and chromatin-immunoprecipitation assays.
37 nal start sites in genome-wide sequencing of chromatin immunoprecipitations assays.
43 lts of both gene expression and cross-linked chromatin immunoprecipitation assay analyses identified
44 of techniques used in the study, such as the chromatin immunoprecipitation assay and assays for trans
45 eraction with IRS-2 promoter was analyzed by chromatin immunoprecipitation assay and glucose-induced
46 the HIF1alpha gene promoter as shown by the chromatin immunoprecipitation assay and is required for
47 site in human RANTES promoter as revealed by chromatin immunoprecipitation assay and protein-DNA bind
48 .3 loading on viral chromatin as measured by chromatin immunoprecipitation assays and enhances viral
49 retic mobility shift assays, and in vivo, by chromatin immunoprecipitation assays and expression anal
51 efine the molecular events involved, we used chromatin immunoprecipitation assays and found that RA p
53 site demonstrated by luciferase reporter and chromatin immunoprecipitation assays and is sufficient t
55 Furthermore, sequence analysis coupled with chromatin immunoprecipitation assays and reporter gene a
56 assay, electrophoretic mobility shift assay, chromatin immunoprecipitation assay, and coimmunoprecipi
57 ound the endogenous C/EBPalpha promoter in a chromatin immunoprecipitation assay, and NF-kappaB p50 t
58 ivity, reduces c-Maf binding to the IL-4p in chromatin immunoprecipitation assays, and enhances c-Maf
59 through genetic ablation of critical genes, chromatin immunoprecipitation assays, and house dust mit
60 s, small GTPase activity, luciferase assays, chromatin immunoprecipitation assays, and network analys
65 ng data from large-scale sequencing of a HAc chromatin immunoprecipitation assay (ChIP-Seq) would imp
71 ene promoter by bioinformatics analysis, and chromatin immunoprecipitation assay confirmed that NF-ka
82 onucleotides, site-directed mutagenesis, and chromatin immunoprecipitation assays confirmed the funct
84 ith electrophoretic mobility shift assay and chromatin immunoprecipitation assay demonstrate direct i
85 ransgenic mouse embryo fibroblasts (MEF) and chromatin immunoprecipitation assays demonstrate endogen
88 ter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that st
99 ntaining the -85-bp and -345-bp sites, while chromatin immunoprecipitation assays demonstrated enhanc
106 Electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrated that G
107 Analysis of the Fpn promoter and in vivo chromatin immunoprecipitation assays demonstrated that H
110 outhwestern blot, electromobility shift, and chromatin immunoprecipitation assays demonstrated that K
113 s against NF-Y subunits) studies, as well as chromatin immunoprecipitation assay, demonstrated the bi
114 he neuronal Pomc enhancers nPE1 and nPE2 and chromatin immunoprecipitation assays detected in vivo bi
115 ey cell-cycle regulators including E2F2, and chromatin immunoprecipitation assays detected Mtg16 near
116 dentify a YY1-binding site at +25 in P2, and chromatin immunoprecipitation assays detected YY1 bindin
120 ion factor STAT1alpha reporter construct and chromatin immunoprecipitation assay for the inducible ni
128 analysis, electrophoretic mobility shift and chromatin immunoprecipitation assays further showed the
131 ent transfection, luciferase reporter assay, chromatin immunoprecipitation assay, gel-shift assay, co
136 p63 promoter mutagenesis, transfection and chromatin immunoprecipitation assays identified a C/EBPa
137 alysis of the mechanism using expression and chromatin immunoprecipitation assays identified a subset
141 clear receptor corepressor 2 repression, and chromatin immunoprecipitation assays identified peroxiso
143 to DR-11, but not to Pal-17, was detected by chromatin immunoprecipitation assay in ATRA-treated cell
144 formaldehyde-based in vivo cross-linking and chromatin immunoprecipitation assay in conjunction with
145 overexpression/knockdown and luciferase and chromatin immunoprecipitation assays in cardiomyocytes a
146 reaction, Western blots, flow cytometry, and chromatin immunoprecipitation assays in ERalpha- and HER
149 s, were found to bind Stat5b by quantitative chromatin immunoprecipitation assays in liver chromatin
151 ssociates with Hoxa9 and Hoxa10 promoters in chromatin immunoprecipitation assays in these cells, sug
152 NA, we performed binding assays in vitro and chromatin immunoprecipitation assays in U2OS cells.
154 R on UGT2B7 gene expression was validated in chromatin immunoprecipitation assays in which TCPOBOP tr
155 ined by immunoblotting, immunoprecipitation, chromatin immunoprecipitation assay, in vitro binding as
168 uced activation of the promoter, as shown by chromatin immunoprecipitation assays, mutational analysi
172 the number of TF interactions obtained from chromatin immunoprecipitation assays or determined by ye
175 kappaB binding to the human LCN2 promoter in chromatin immunoprecipitation assays performed in human
177 Electrophoretic mobility shift assays and chromatin immunoprecipitation assay quantitative polymer
178 ion was determined by reporter transfection, chromatin immunoprecipitation assays, quantitative rever
179 rmed in vitro and in vivo by super-shift and chromatin immunoprecipitation assays, respectively.
180 ion of the EDNRB gene in transactivation and chromatin immunoprecipitation assays; results were valid
189 ies using the luciferase reporter system and chromatin immunoprecipitation assay revealed that IFNalp
193 e regions that mediate the repression, and a chromatin immunoprecipitation assay revealed that more I
200 ssion caused an upregulation of miR-200c and chromatin immunoprecipitation assays revealed endogenous
210 pitulated these gene expression changes, and chromatin immunoprecipitation assays revealed that HDACi
229 Electrophoretic mobility shift assay and chromatin immunoprecipitation assays showed inhibited St
232 ncing of BRD4, an important BET protein, and chromatin immunoprecipitation assays showed that JQ1 alt
241 , single-molecule in situ hybridization, and chromatin immunoprecipitation assays showed that vIRF4 n
242 ulate the activity of the VEGF promoter, and chromatin immunoprecipitation assays showed that WT1 can
247 quencing-mediated transcriptome analysis and chromatin immunoprecipitation assays, suggesting that MY
248 Phosphoimmunoblotting studies, as well as chromatin immunoprecipitation assays targeting the IFN-b
250 L3.6pL cells showed by knockdown of EZH2 and chromatin immunoprecipitation assays that HOTAIR-mediate
251 E promoter and demonstrated, using EMSAs and chromatin immunoprecipitation assays, that AP-2alpha cou
252 ow, using electrophoretic mobility shift and chromatin immunoprecipitation assays, that phosphorylati
254 g to its own promoter as demonstrated by the chromatin immunoprecipitation assay; therefore, Sp1 is a
256 the kinetics of proviral reactivation using chromatin immunoprecipitation assays to measure changes
257 cipitation, yeast two-hybrid, gel shift, and chromatin immunoprecipitation assays) to identify and co
264 a combination of expression, luciferase, and chromatin immunoprecipitation assays we demonstrate that
268 asis of global gene expression profiling and chromatin immunoprecipitation assay, we found ITPR1 (ino
270 g, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay, we found that hTERT
271 Moreover, using Dleu2 promoter analysis by chromatin immunoprecipitation assay, we have shown that
273 SHH promoter (deletion mutant) reporter, and chromatin immunoprecipitation assays, we demonstrate tha
282 ng immunohistochemical, transcriptional, and chromatin immunoprecipitation assays, we further discove
284 , electrophoretic mobility shift assays, and chromatin immunoprecipitation assays, we identified and
286 growth, luciferase reporter, expression, and chromatin immunoprecipitation assays, we identify GLI1,
287 east two-hybrid, co-immunoprecipitation, and chromatin immunoprecipitation assays, we show that Like
295 by electrophoretic mobility shift assay and chromatin immunoprecipitation assay, which showed increa
296 Vav3 was further demonstrated by sequential chromatin immunoprecipitation assays, which revealed tha
297 LF11 specifically associates with Area II in chromatin immunoprecipitation assays, while preventing b
298 tissues and mouse and human hepatocytes, and chromatin immunoprecipitation assays with mouse liver.
300 tadpoles treated with or without T3 and for chromatin immunoprecipitation assays with these chips, w